Skip to content
Peptigraph home

Tesamorelin reconstitution calculator

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Educational use only
1Vial size
2Bacteriostatic water added
3Dose per injection
4Syringe (U-100)
Draw to
20units
= 0.2 mL on a 1 mL U-100 insulin syringe
10 mg vial2 mL water1 mg dose
Concentration
5 mg/mL
Doses per vial
10
Weeks (1 dose/wk)
10
Math only. It does not recommend a dose. Tesamorelin: FDA approved (Egrifta).

20 units (0.2 mL) on a 1 mL U-100 syringe: 1 mg from a 10 mg vial + 2 mL water (Tesamorelin).

Dosing table for a 10 mg vial

Syringe units (U-100) for each dose, by how much bacteriostatic water you add.

Tesamorelin: U-100 syringe units per dose for a 10 mg vial
Dose1 mL water2 mL water2.5 mL water3 mL water
0.5 mg51012.515
1 mg10202530
1.5 mg153037.545
2 mg20405060
2.5 mg255062.575
3 mg30607590

How the math works

Concentration is the vial's milligrams divided by the water you add. Volume to draw is your dose divided by that concentration. On a U-100 syringe, 1 mL is 100 units, so units = mL × 100.

10 mg ÷ 2 mL = 5 mg/mL
1 mg ÷ 5 mg/mL = 0.2 mL
0.2 mL × 100 = 20 units

How many units is 1 mg of Tesamorelin?

With a 10 mg vial and 2 mL of bacteriostatic water, 1 mg is 20 units (0.20 mL) on a U-100 syringe. With 1 mL of water it is 10 units. The answer always depends on how much water was added.

How much bacteriostatic water for a 10 mg Tesamorelin vial?

The water only sets the concentration; the amount of Tesamorelin in the vial stays the same. 2 mL makes 5 mg/mL, so 1 mg is 20 units. 2.5 mL makes 4 mg/mL, so the same 1 mg is 25 units. More water makes small doses easier to measure but needs more volume per injection.

How many 1 mg doses are in a 10 mg vial?

10 ÷ 1 = 10, so 10 full doses of 1 mg. Any liquid lost in the needle and vial is not counted.

How much bac water for 10mg tesamorelin?

The water volume is a free choice and only sets the concentration: 1 mL gives 10 mg per mL, 2 mL gives 5 mg per mL and 5 mL gives 2 mg per mL. The Egrifta WR label itself uses 1.3 mL for 11.6 mg.

Calculated from vial mg 10; water m L 1, 2, 5. Formula: 10 / 1 = 10; 10 / 2 = 5; 10 / 5 = 2 mg per mL

How do you reconstitute tesamorelin?

For the approved Egrifta WR product, the label instructs to swirl and not shake after adding the diluent.[3]

Is there a tesamorelin 20mg vial?

The Egrifta SV label describes a 2 mg vial, and the WR label describes a single larger vial; neither label mentions the bigger research-use sizes that people search for.[4]

What is the labelled tesamorelin dose in units?

On a U-100 syringe 0.35 mL (the Egrifta SV dose of 1.4 mg) is 35 units, a strength of 4 mg per mL, while the Egrifta WR dose of 1.28 mg in 0.16 mL is 16 units, a strength of 8 mg per mL. The two are not substitutable.

Calculated from SV dose mg 1.4, volume m L 0.35; WR dose mg 1.28, volume m L 0.16; units per m L 100. Formula: units = volume_mL x 100; mg per mL = dose_mg / volume_mL

Preset doses are round numbers for the arithmetic, not dosing guidance. Vial sizes are the ones most often mentioned for Tesamorelin in community discussions.

20 units · 0.2 mL · 1 mg from 10 mg + 2 mL

Tesamorelin vial strengths on the FDA labels

Egrifta WR is labelled as a single-patient-use vial of 11.6 mg of tesamorelin, supplied with a multiple-dose bottle of bacteriostatic water.[3]

The label sets the mixing volume at 1.3 mL and gives the resulting strength as 8 mg per mL.[3]

The older Egrifta SV is a different product: a 2 mg single-dose vial with 10 mL of sterile water.[4]

The labelled dose of Egrifta WR is a fixed 1.28 mg, not the round-number doses used in the trials below. A research-use vial has no label strength to check against.[3]

At the labelled 8 mg per mL, the labelled 1.28 mg dose is 0.16 mL, which reads as 16 units on a U-100 syringe. A 1 mL U-100 syringe is marked to 100 units, so 1 unit is 0.01 mL.

Calculated from dose mg 1.28; concentration mg per m L 8; u100 units per m L 100. Formula: 1.28 / 8 = 0.16 mL; 0.16 x 100 = 16 units

Trial doses worked through on this calculator

The large 26-week randomized trial in HIV-associated abdominal fat used a fixed amount: 2 mg injected under the skin every day.[5]

A 12-week dose-ranging trial tested both 1 mg and 2 mg once daily against placebo.[6]

A small pilot in people with normal cognition to mild cognitive impairment used 1 mg.[7]

If a 2 mg dose came from a 10 mg research vial mixed with 2 mL, the concentration would be 5 mg per mL and the dose would measure 40 units. Mixed with 1 mL it is 10 mg per mL and 20 units.

Calculated from dose mg 2; vial mg 10; water m L 2, 1. Formula: 10 / 2 = 5 mg/mL; 2 / 5 x 100 = 40 units. 10 / 1 = 10 mg/mL; 2 / 10 x 100 = 20 units

The same 10 mg vial holds 5 doses of 2 mg, so at a once-daily schedule it would be empty after 5 days, well inside the 7-day discard window printed on the Egrifta WR label.

Calculated from vial mg 10; dose mg 2. Formula: 10 / 2 = 5 doses

Where tesamorelin arithmetic goes wrong

The label states that a reconstituted Egrifta WR vial provides daily doses for 7 days, not until empty.[3]

7 doses of 1.28 mg use 8.96 mg of the 11.6 mg in the vial, so about 2.64 mg is not used. Dividing 11.6 by 1.28 to count 9 doses ignores the label discard rule.

Calculated from vial mg 11.6; dose mg 1.28; days 7. Formula: 7 x 1.28 = 8.96 mg; 11.6 - 8.96 = 2.64 mg

The SV and WR labels warn that they are not substitutable, so a unit count worked out for either cannot be carried to the other.[3]

Egrifta SV dose in volume

The Egrifta SV label gives its dose as 1.4 mg, which is 0.35 mL of the reconstituted solution.[4]

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3EGRIFTA WR prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  4. 4EGRIFTA SV prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  5. 5Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
  6. 6A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.AIDS (London, England) · 2005PMID 16052083Accessed 2 Oct 2026
  7. 7The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026

Found an error? Report a correction.